Benzinga | Jul 22, 2020 07:25AM EDT

CytoSorbents Prices ~5.263M Share Common Stock Offering At $9.50/Share

MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb(r) blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the pricing of its previously announced underwritten public offering of 5,263,158 shares of its common stock at a public offering price of $9.50 per share, resulting in gross proceeds of approximately $50.0 million before deducting underwriting discounts and commissions and other offering expenses.